PRESS RELEASE published on 09/24/2024 at 14:00, 1 year 7 months ago Lonza and Vertex Sign a Long-Term Commercial Supply Agreement for CASGEVY® (exagamglogene autotemcel) Lonza and Vertex sign a long-term commercial supply agreement for CASGEVY® cell therapy based on CRISPR/Cas9 gene-editing technology. Lonza to manufacture at Geleen, NL facility approved by FDA, EMA, and MHRA Lonza Cell Therapy Vertex CASGEVY® CRISPR/Cas9
BRIEF published on 08/28/2024 at 18:36, 1 year 8 months ago Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds Lonza EUR 1.2 Billion Corporate Financing Dual-Tranche Bonds Luxembourg Listing
BRIEF published on 08/28/2024 at 18:36, 1 year 8 months ago Lonza fixe le prix d'une émission d'obligations à deux tranches de 1,2 milliard d'euros Lonza Financement Des Entreprises Obligations À Double Tranche 1,2 Milliard D'euros Cotation Au Luxembourg
PRESS RELEASE published on 08/28/2024 at 18:31, 1 year 8 months ago Lonza Prices EUR 1.2 Billion Dual-Tranche Straight Bonds Lonza Group AG's wholly-owned Lonza Finance International NV prices dual-tranche EUR 1.2 billion straight bonds with 3.25% and 3.50% coupons for six and ten years respectively. Bonds to be listed on Luxembourg Stock Exchange for general corporate purposes Lonza Group AG Listing EUR 1.2 Billion Luxembourg Stock Exchange Straight Bonds
BRIEF published on 07/25/2024 at 07:05, 1 year 9 months ago Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members Pharmaceutical Industry Lonza Board Nominations Juan Andres Eric Drapé
BRIEF published on 07/25/2024 at 07:05, 1 year 9 months ago Lonza nomme Juan Andres et Eric Drapé comme membres indépendants du conseil d'administration Lonza Industrie Pharmaceutique Nominations Au Conseil D'administration Juan Andres Eric Drapé
PRESS RELEASE published on 07/25/2024 at 07:00, 1 year 9 months ago Lonza Nominates Juan Andres and Eric Drapé as Independent Board Members Lonza nominates Juan Andres and Eric Drapé as independent board members to enhance governance and expertise. The nominees bring decades of leadership in the pharmaceutical industry Pharmaceutical Industry Lonza Juan Andres Eric Drapé Independent Board Members
BRIEF published on 07/25/2024 at 07:00, 1 year 9 months ago Lonza Group H1 2024 Performance on Track: Sales Increase 1.8% CER, CORE EBITDA Margin at 29.2% Financial Performance Sales Growth Lonza Group H1 2024 Results CORE EBITDA
BRIEF published on 07/25/2024 at 07:00, 1 year 9 months ago Performance du groupe Lonza au premier semestre 2024 en bonne voie : augmentation des ventes de 1,8 % TCC, marge d'EBITDA CORE à 29,2 % Performance Financière Résultats Du Premier Semestre 2024 La Croissance Des Ventes Groupe Lonza EBITDA DE BASE
PRESS RELEASE published on 07/25/2024 at 06:55, 1 year 9 months ago Lonza Group H1 2024 Performance Well On Track to Deliver Full-Year Outlook: Sales Up 1.8% CER and 29.2% CORE EBITDA Margin Lonza Group H1 2024 performance on track: 1.8% sales increase, 29.2% CORE EBITDA margin. Full-Year Outlook confirmed CORE EBITDA Margin Sales Increase Full-year Outlook Lonza Group H1 2024 Performance
Published on 05/11/2026 at 09:05, 3 hours 6 minutes ago Ameriwest Outlines Multiple Additional Breccia Pipe-Style Targets at Bornite from Historical Soil Sampling and Mapping
Published on 05/11/2026 at 08:05, 4 hours 6 minutes ago Tocvan Accelerates Gran Pilar: 5,000+ Meters Drilled to Date, Historic Workings Discovered on South Block, Pilot Progresses
Published on 05/09/2026 at 01:30, 2 days 10 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/11/2026 at 11:36, 35 minutes ago LION Smart and LEAPENERGY secure the performance of their storage containers through multiple guarantees
Published on 05/11/2026 at 11:17, 54 minutes ago Aroundtown SA: Release of a capital market information
Published on 05/11/2026 at 11:10, 1 hour 1 minute ago Original-Research: Schloss Wachenheim AG (von First Berlin Equity Research GmbH): Buy
Published on 05/11/2026 at 11:09, 1 hour 2 minutes ago Marinomed Biotech AG announces progress with Tacrolimus Eyedrops for Entry into the Compounding Market
Published on 05/11/2026 at 10:48, 1 hour 23 minutes ago GUILLEMOT CORPORATION | Weekly report share buyback from May 4 to May 8 2026
Published on 05/11/2026 at 10:48, 1 hour 23 minutes ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 4 au 8 mai 2026
Published on 05/11/2026 at 09:16, 2 hours 55 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 28 avril 2026
Published on 05/07/2026 at 19:15, 3 days 16 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 16 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote